Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux
El. Volk et al., Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux, CANCER RES, 60(13), 2000, pp. 3514-3521
Cellular resistance to the antifolate methotrexate (MTX) is often caused by
target amplification, uptake defects, or alterations in polyglutamylation.
Here we have examined MTX cross-resistance in a human breast carcinoma cel
l line (MCF7/MX) selected in the presence of mitoxantrone, an anticancer ag
ent associated with the multidrug resistance (MDR) phenotype. Examination o
f protein expression and enzyme activities shea ed that MCF7/MX cells displ
ayed none of the classical mechanisms of MTX resistance. They did, however,
exhibit an ATP-sensitive accumulation defect accompanied by reduced polygl
utamylation. Although the kinetics of drug uptake was similar between paren
tal and resistant cells, the resistant cells exhibited increased energy-dep
endent drug efflux. This suggested the involvement of an ATP-binding casset
te (ABC) transporter. However, cells transfected with the breast cancer res
istance protein (BCRP)-the ABC transporter known to be highly overexpressed
in MCF7/MX cells and to confer mitoxantrone resistance (D. D. Ross et al,
J, Natl. Cancer Inst. 91: 429-433, 1999)-were not MTX resistant, which sugg
ested that this transporter is not involved in MTX cross-resistance. Moreov
er, members of the MRP protein family of transport proteins, which had prev
iously been implicated in MTX resistance, were not found to be overexpresse
d in the MCF7/MX cells, Thus, our data suggest that a novel MTX-specific ef
flux pump may be involved in this unusual cross-resistance phenotype.